Zinuara Pharma

Zenara Pharma is an India-based pharmaceutical company focused on development and manufacturing of finished dosage products, particularly affordable generic and specialty formulations. The company operates as a Biophore group company and has been described as a vertically integrated pharma business spanning research, development, manufacturing, quality, and compliance. Publicly reported products and approvals indicate activity in oral solid and related dosage forms, including nicotine replacement products, modified-release tablets, hard gelatin capsules, cannabidiol oral solution, and generic sertraline hydrochloride capsules. In July 2025, Zenara received U.S. FDA approval for its ANDA for sertraline hydrochloride capsules, including 180-day Competitive Generic Therapy exclusivity for the first generic version. Overall, Zenara appears to be a commercial-stage generic/specialty pharmaceutical manufacturer rather than a clinical-stage biotech innovator.